Thurston Springer Miller Herd & Titak’s Royalty Pharma RPRX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22K	Hold	393	–	–	0.01%	661
2026 Q1	$18.9K	Hold	393	–	–	0.01%	781
2025 Q4	$15.2K	Buy	+393	New	+$15K	0.01%	827
2025 Q3	–	Sell	-393	Closed	-$14.2K	–	1196
2025 Q2	$14.2K	Hold	393	–	–	﹤0.01%	1056
2025 Q1	$12.2K	Buy	+393	New	+$12.5K	﹤0.01%	1046

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's RPRX Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its Royalty Pharma (RPRX) position steady in Q2 2026 at 393 shares worth $22K. The position accounts for 0.01% of the portfolio, ranked #661.

Thurston Springer Miller Herd & Titak first reported a position in RPRX in Q1 2025 and has held it in 5 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Thurston Springer Miller Herd & Titak held 393 shares of Royalty Pharma worth $22K as of Q2 2026.
Thurston Springer Miller Herd & Titak left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up 0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #661 holding.
Thurston Springer Miller Herd & Titak first reported a position in Royalty Pharma in Q1 2025 and has held it in 5 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.